Progression of renal disease: current concepts and therapeutic approaches.
The pathogenesis of progressive renal disease includes systemic hypertension and intrarenal factors that may be hemodynamic or metabolic in origin and involve mediators of inflammation. Most current information derives from experiments in rodents. In other species (rabbit, dog, baboon) subjected to renal mass reduction, a greater variety of pathologic changes is apparent than in rats. Clinical trials at controlling progression of renal disease are compounded by numerous factors; and it is not evident that extrapolation can safely be made from results of animal studies to human disease. The mechanism(s) of renal disease progression in humans, therefore, remain largely unknown. Current therapeutic recommendations in patients with chronic renal disease include limitation of phosphorus absorption, correction of lipid abnormalities and control of systemic blood pressure. The latter can be achieved with a variety of agents some of which, like angiotensin converting enzyme inhibitors and calcium antagonists, may be preferred because of specific intrarenal effects.
Bourgoignie
J J
JJ
University of Miami School of Medicine, Division of Nephrology, Florida.
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004044:Dietary Proteins / Q000008:administration & dosage; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D009399:Nephrons / Q000293:injuries; D016226:Phosphorus, Dietary / Q000008:administration & dosage; D012079:Renal Circulation
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004044:Dietary Proteins; D016226:Phosphorus, Dietary